TMEDRP is a novel two-stage learning framework that integrates tumor-intrinsic signatures and TME-specific components for enhanced clinical drug response prediction and exhibits promising zero-shot generalization across unseen cancer lineages and novel compounds, suggesting its robustness across diverse scenarios.
Abstract
Abstract Motivation Clinical drug response prediction is constrained by the paucity of patient data, forcing a reliance on in vitro cell line models. Current transfer learning-based methods typically focus on learning domain-invariant representations, but often overlook the critical role of tumor microenvironment (TME) during cross-domain translation. Given that TME discrepancies between in vitro and in vivo settings are critical factors of therapeutic resistance, explicitly modeling the TME is essential to bridge the gap between preclinical models and patient-specific responses. Results We propose TMEDRP, a novel two-stage learning framework that integrates tumor-intrinsic signatures and TME-specific components for enhanced clinical drug response prediction. TMEDRP introduces TME influences via a pathway-informed disentanglement strategy, a neural co-expression module, and an uncertainty-driven adaptation mechanism. Extensive benchmarks demonstrate that TMEDRP outperforms existing state-of-the-art methods. Importantly, it exhibits promising zero-shot generalization across unseen cancer lineages and novel compounds, suggesting its robustness across diverse scenarios. Furthermore, quantitative analysis of the model’s latent embeddings uncovers key tumor-intrinsic pathways and extrinsic TME factors that distinguish drug-sensitive from resistant cohorts. The identified shared and drug-specific molecular markers align with established clinical mechanisms, supporting the model’s biological interpretability and clinical utility. Availability and implementation The code and results are available at https://github.com/kybinn/TMEDRP.
UniCure is presented, a multi-modal model that combines biological and chemical foundation models to predict drug-induced transcriptomic responses across diverse cell and tissue contexts, enabling individualized drug ranking.
Ze-Xi Chen, Saisai Tian, Jia-Zheng Pei et al.· Cancer Cell· 0 citations
An AI-driven multi-omics model using GDSC, CCLE, DepMap, CTRP, and TCGA data, integrating mutation, copy-number variation, RNA expression, DNA methylation, drug SMILES, and IC50/AUC responses is developed, demonstrating that multi-omics fusion and drug-structure modeling improve prediction stability and support interpr...
Xin-Yuan Kang, Ai-Lin Deng· Applied and Computational En...· 0 citations
A translational framework combining patient-centric benchmarking with a pan-cancer pharmacogenomic atlas of patient-derived organoids and a deep learning model integrating transcriptomic and chemical information to predict drug response and prioritize therapies is introduced, supporting NELLY as a promising framework f...
C. Peralta Viteri, N. Harnischfeger, Lili Szabo et al.· bioRxiv· 0 citations
AET5 is presented, a de novo molecular generation framework that conditions molecular design on disease-reversal gene expression profiles, providing a general framework for biologically informed drug design under noisy transcriptomic conditions.
Zhi-Kang Yuan, Xin Zhang, Gao-Ming Lin et al.· PLoS Computational Biology· 0 citations
CaMeRe, a Causally-inspired Meta-representation learning framework designed to predict patient-specific clinical Response to drug combinations, exhibited robust multi-domain generalization performance across multiple clinical drug combination response datasets and PDXs drug combination response datasets and generalizat...
Qing-Qing Zhang, Shao-Wu Zhang, Ming-Hui Shi et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.